A Swedish translation of the prospectus summary is available
Cessatech A/S ("Cessatech") announces that a Swedish translation of the prospectus summary is available on the websites of Cessatech (www.cessatech.com), Sedermera Fondkommission (www.sedermera.se) and Spotlight Stock Market (www.spotlightstockmarket.com).
Introduction video: https://cessatech.com/wp-content/uploads/2020/11/CessatechTeaser1_LR.mp4
For additional information on the issue of units, please contact:
Phone: +46 (0) 40-615 14 10
For more information, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.
FluoGuide obtains patent protection for FG001 in Australia
Copenhagen, Denmark, 30 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that the Company has successfully secured patent protection for its lead clinical asset FG001 in Australia. The protection is granted by the Australian Commissioner of Patents. The patent number is 2015317...
SEB initiates commissioned research on FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequen...
Peptonic Medicals dotterbolag lanserar återanvändbar och miljövänlig tygbinda
Pionjären inom finländsk femtech, menskoppstillverkaren Lune Group Oy Ltd., utökar sitt produktsortiment med en återanvändningsbar tygbinda. Bindorna är hudvänliga och lämpar sig för användning under menstruation, lindrig inkontinens eller som ett tilläggsskydd tillsammans med Lunette®menskopp...
Brighter’s Nomination Committee for the Annual Shareholders’ Meeting 2021
Brighter’s Nomination Committee for the Annual Shareholders’ Meeting 2021 has been appointed based on the ownership structure as of 30 September 2020 in line with the nomination committee instruction that was adopted at the 2020 Annual General Meeting. The Nomination Committee shall consist of Brigh...